USD 1.07 Billion
Report ID:
SQMIG35D2145 |
Region:
Global |
Published Date: March, 2024
Pages:
219
|Tables:
88
|Figures:
76
Global Preeclampsia Diagnostics Market size was valued at USD 1.07 Billion in 2022 and is poised to grow from USD 1.11 Billion in 2023 to USD 1.50 Billion by 2031, growing at a CAGR of 3.8% in the forecast period (2024-2031).
The global preeclampsia diagnostics market is exhibiting notable growth due to increasing awareness about maternal health and pregnancy-related complications. Preeclampsia, a hypertensive disorder, remains a significant concern in obstetrics, leading to a growing demand for accurate and early diagnostic methods. This has prompted key market players to focus on developing innovative diagnostic technologies that enable early detection and management of preeclampsia.
Additionally, rising healthcare expenditure, improving healthcare infrastructure in developing regions, and the integration of advanced medical technologies into obstetric care practices are contributing to the expansion of the preeclampsia diagnostics market.
However, challenges such as the high cost associated with advanced diagnostic methods and limited accessibility to quality healthcare in certain regions could potentially hinder market growth. As researchers continue to explore novel biomarkers and non-invasive diagnostic approaches, the preeclampsia diagnostics market is expected to witness further advancements in the coming years.
US Preeclampsia Diagnostics Market is poised to grow at a sustainable CAGR for the next forecast year.
Global Market Size
USD 1.07 Billion
Largest Segment
Blood Tests
Fastest Growth
Blood Tests
Growth Rate
3.8% CAGR
To get more reports on the above market click here to Buy The Report
The global preeclampsia diagnostics market is segmented on the basis of Test Type, Product, End-user, and Region. By test type, it is divided into Blood Tests, Urine Analysis. The product segment includes Instruments, Consumables. The end-user includes Hospitals, Specialty Clinics, Diagnostic Centres, Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Preeclampsia Diagnostics Market Analysis by Test Type
Between blood and urine tests in the global Preeclampsia diagnostics market, blood tests currently dominate as the preferred test type. This dominance can be attributed to the fact that blood tests, such as the measurement of biomarkers like soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF), provide more accurate and reliable results for early detection and monitoring of Preeclampsia. These biomarkers offer insights into the imbalance of angiogenic factors in the maternal bloodstream, aiding in the prediction and diagnosis of the condition.
However, urine tests are currently experiencing faster growth. This can be attributed to their non-invasive nature and ease of sample collection, which makes them more convenient for both patients and healthcare providers. Urine tests for preeclampsia often rely on detecting specific biomarkers that are indicative of the condition, allowing for early diagnosis and intervention. As a result, these tests have gained popularity, particularly in regions with limited access to advanced healthcare facilities. Additionally, ongoing research and development efforts are focused on enhancing the accuracy and reliability of urine-based diagnostic methods, further driving their rapid adoption and growth within the market.
Preeclampsia Diagnostics Market Analysis by Product
Between consumables and instruments in the product segment of the global Preeclampsia diagnostics market, consumables are currently dominating. This growth in this segment can also be attributed to the increasing instances of preeclampsia among pregnant women and the widespread acceptance of biomarker-based diagnostics. Moreover, the heightened awareness of this condition and various detection techniques is anticipated to drive the demand for consumables in the foreseeable future.
Between consumables and instruments under the product, consumables are experiencing faster growth. This can be attributed to the recurring nature of consumable purchases in diagnostic procedures, including test kits, reagents, and disposable components. As demand for accurate and frequent preeclampsia screenings rises, the need for these consumables remains consistent. Moreover, advancements in research are leading to the development of improved and specialized consumables, further driving their adoption.
To get detailed analysis on other segments, Request For Free Sample Report
North America asserts its dominance in the global preeclampsia diagnostics market due to a combination of factors. The region's advanced healthcare infrastructure, robust research and development capabilities, and high levels of awareness about maternal health contribute significantly to its leading position. Moreover, North America benefits from strong collaborations between research institutions, healthcare providers, and industry players, facilitating the rapid adoption of cutting-edge diagnostic technologies.
Asia-Pacific is emerging as the fastest-growing market for preeclampsia diagnostics globally. This growth can be attributed to several factors, including a rising awareness of maternal health, increasing healthcare investments, and improving healthcare infrastructure in countries across the region. Additionally, a higher prevalence of preeclampsia due to factors like changing lifestyles and delayed pregnancies has fueled the demand for advanced diagnostic methods. The region's large population, combined with efforts to enhance prenatal care and reduce maternal mortality rates, has led to an increased adoption of preeclampsia diagnostic technologies.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Preeclampsia Diagnostics Market Drivers
Growing Focus on Development of Innovative Preeclampsia Diagnostic Products
Early detection of hypertensive disorders during pregnancy has long posed a challenge. With a surge in preeclampsia cases and a pressing need to lower maternal and neonatal mortality rates, there's a growing window for innovative preeclampsia diagnostic tools. The emergence of point-of-care tests for early preeclampsia diagnosis holds promise in curbing unnecessary hospital admissions, thereby alleviating the associated costs. Addressing the risk of preterm birth, major market players are fostering strategic collaborations to introduce advanced diagnostic solutions. The market's trajectory is expected to be influenced by evolving biomarker tests and a wave of product launches, driving progress throughout the projected period.
Preeclampsia Diagnostics Market Restraints
Less Awareness about Preeclampsia in Developing Regions –
Request Free Customization of this report to help us to meet your business objectives.
The competitive landscape of the global preeclampsia diagnostics market is characterized by a dynamic interplay of research and development efforts aimed at introducing innovative diagnostic solutions. Market players are striving to enhance the accuracy and accessibility of diagnostic methods, particularly those that enable early detection and monitoring of preeclampsia. Collaboration and partnerships between diagnostic technology providers and healthcare institutions are fostering the integration of advanced diagnostic tools into obstetric care practices.
Additionally, advancements in biomarker research and the introduction of novel diagnostic products are contributing to the market's growth trajectory. As competition intensifies, companies are focusing on differentiation through technology advancements and strategic alliances to gain a competitive edge in this evolving landscape.
Preeclampsia Diagnostics Market Top Player’s Company Profiles
Preeclampsia Diagnostics Market Recent Developments
Thermo Fisher's immunoassays for assessing preeclampsia risk were approved by the FDA in May 2023. Preeclampsia risk assessment and clinical management will be aided by these immunoassays, which are the first to be cleared by the FDA and designated as breakthroughs. This represents a major advancement in the treatment of this serious pregnancy condition.
In May 2023, Sera Prognostics Inc., unveiled a series of commercial transformations. With a steadfast commitment to enhancing the well-being of mothers and newborns, the company pioneered innovative pregnancy biomarker information, empowering both doctors and patients alike.
At the 20th World Congress in Fetal Medicine in Valencia, Spain, in June 2023, Diabetomics presented the findings of clinical trials on first-trimester screening and diagnostic support for preeclampsia. The findings showed that the FMF 'Triple' screening test for preterm preeclampsia has significantly increased screening performance with the addition of GlyFn as a supplemental biomarker; nevertheless, additional validation in various populations is required to corroborate these findings.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
Based on our global preeclampsia diagnostics market analysis, The global preeclampsia diagnostics market is experiencing significant growth driven by a combination of factors. The increasing awareness about maternal health and the potential risks associated with preeclampsia has led to a higher demand for accurate and timely diagnostic methods. This demand is further fuelled by the rising prevalence of preeclampsia globally.
One notable trend within the market is the growing adoption of advanced diagnostic technologies, including biomarker-based tests and imaging techniques. These innovations enable healthcare professionals to identify biomarkers and physiological changes associated with preeclampsia, offering better insights into disease progression and severity.
While the market is poised for growth, certain challenges must be addressed. The high cost of advanced diagnostic methods and limited accessibility to quality healthcare in certain regions could impede market expansion. Additionally, regulatory complexities and reimbursement issues might affect the adoption of novel diagnostics.
In conclusion, the global preeclampsia diagnostics market is witnessing a shift towards early risk assessment and improved diagnostic accuracy. This trend aligns with the broader healthcare objectives of reducing maternal and fatal complications, thereby driving the development and adoption of innovative diagnostic solutions. However, addressing cost-related barriers and ensuring equitable access to these advancements will be crucial for the sustained growth of the market.
Report Metric | Details |
---|---|
Market size value in 2022 | USD 1.07 Billion |
Market size value in 2031 | USD 1.50 Billion |
Growth Rate | 3.8% |
Base year | 2023 |
Forecast period | 2024-2031 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Preeclampsia Diagnostics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Preeclampsia Diagnostics Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Preeclampsia Diagnostics Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Preeclampsia Diagnostics Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35D2145
sales@skyquestt.com
USA +1 351-333-4748